Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1076-1085

  Jilaveanu, Lucia ^a   Zito, Christopher ^a   Lee, Sandra J ^c   Nathanson, Katherine L ^d   Camp, Robert L ^b   Rimm, David L ^b   Flaherty, Keith T ^d   Kluger, Harriet M ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBOPLATIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN SERINE KINASE; SORAFENIB; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARBOPLATIN; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 61549103137     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2280     Document Type: Article

References (50)

1. Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367-71.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Katipamula R, Markovic SN. Emerging therapies for melanoma. Expert Rev Anticancer Ther 2008;8: 553-60.
4. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008;5:e120.
5. Curtin JA, Busam K,Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6.
6. Gogas H, loannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
7. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
8. DhawanP,Singh AB,EllisDL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κBand tumor progression. Cancer Res 2002;62:7335-42.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
10. Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2004;2:46.
11. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
12. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19 -20.
13. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
14. Adnane L,Trail PA,Taylor I,Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and ty- rosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612.
15. Murphy DA, Makonnen S, Lassoued W, Feldman MD,Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006;169:1875-85.
16. Lyons JF,Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
17. Lee JT, Mc Cubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003;4:757-63.
18. Strumberg D, RichlyH, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.
19. Strumberg D, Clark JW, Awada A, etal. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37.
20. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61:535 -48.
21. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). In: Chicago (IL): Proc Am Soc Clin Oncol; 2007.
22. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
23. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
24. Ahmad T, Marais R, Pyle L, etal. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. In: New Orleans (LA): Proc Am Soc Clin Oncol; 2004.
25. Flaherty K, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43 -9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. In: New Orleans (LA): Proc Am Soc Clin Oncol;2004.
26. Flaherty KT, SchillerJ, Schuchter LM, et al. Aphase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14:4836-42.
27. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183-9.
28. Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. In: Chicago (IL): Proc Am Soc Clin Oncol; 2007.
29. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8: 1323-7.
30. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7: 24-31.
31. McCarthy MM, DiVito KA, Sznol M, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006;12:3856-63.
32. Kluger HM, McCarthy MM, Alvero AB, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up- regulated in metastatic melanoma, and XIAP cleavage by phenoxodiol is associated with carboplatin sensitization. J Transl Med 2007;5:6.
33. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of β- catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66:5487-94.
34. McDermott DF, SosmanJA, Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26:2178-85.
35. Amaravadi R, Schuchter LM, Kramer A, et al. Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. In: Atlanta (GA): Proc Am Soc Clin Oncol; 2006.
36. Amaravadi R, Schuchter LM, McDermott DF, et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. In: Chicago (IL): Proc Am Soc Clin Oncol; 2007.
37. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1 L1-PDGFRα and the imatinib-resistant FIP1 L1-PDGFRα T674I mutant. Blood 2006; 108:1374-6.
38. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFR β and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica 2007;92:27-34.
39. Lacal PM, Ruffini F, Pagani E, D'Atri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 2005;27:1625-32.
40. Graells J, Vinyals A, Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004;123:1151-61.
41. Straume O, Akslen LA. Expression of vascular en- dothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223-35.
42. Pisacane AM, Risio M.VEGFandVEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 2005;15:39-43.
43. Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993;190:702-8.
44. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-16.
45. Bunone G,Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76.
46. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M,Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202.
47. Venesio T, Chiorino G, Balsamo A, et al. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 2008;21:716-26.
48. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 2008;128:2003-12.
49. Mouawad R, Comperat E, Cajfinger F, Capron F, Khayat D. Flt-4 and its ligand VEGF-C in metastatic malignant melanoma: relationships to clinicopathological parameters response and survival. In: Chicago (IL): Proc Am Soc Clin Oncol; 2008.
50. Kim KB, Saro J, Moschos SS, et al. A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma. In: Chicago (Il): Proc Am Soc Clin Oncol; 2008.